AG881

Phase 1Small molecule

Institut de Recherches Internationales Servier

AG881 is one of 57 small molecule programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Low Grade GliomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Low Grade GliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

15 2

Trexall

Alnylam Pharmaceuticals

Phase 3

2 3

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 4

Bicnu

MMelissa K Accordino

Phase 3

7 5

Vepesid

AAvyxa

Phase 3

4 6

Photofrin

PPinnacle Biologics Inc.

Phase 3

2 7

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 8

Rayos

RRoxane Laboratories

Phase 3

1 9

Velban

EEastern Cooperative Oncology Group

Phase 3

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Low Grade Glioma1 trial

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT03343197·49 enrolled

Glioma1 trial

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT02481154·95 enrolled

Advanced Hematologic Malignancies1 trial

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Completed·AAgios Pharmaceuticals, Inc.·Phase 1·NCT02492737·46 enrolled

ART1 trial

A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants

Completed·AAgios Pharmaceuticals, Inc.·Phase 1·NCT04145128·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AG881. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AG881 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AG881. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Recherches Internationales Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Institut de Recherches Internationales Servier

AG881

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Low Grade Glioma1 trial

Glioma1 trial

Advanced Hematologic Malignancies1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News